← Eichor
Study identifier: NCT04218318 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn

Condition: Hemolytic Disease of Newborn · Neonatal Hyperbilirubinemia  ·  Sponsor: Ministry of Health, Saudi Arabia

PhaseNA
Planned participants84
Who can joinAll sexes, 1 Hour to 14 Days
Healthy volunteersYes

About this study

We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn. Objectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.

This description comes directly from the study's public registry record.

Talk to the study team

Fatimah S Alhazmi, MD  ·  00 966 54 0564141  ·  f.alhazmi@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Madinah maternity and children's hospitalMadinah, Saudi ArabiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04218318